Literature DB >> 3095287

Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites.

Y Shibamoto, Y Yukawa, K Tsutsui, M Takahashi, M Abe.   

Abstract

Radiobiologically hypoxic fractions of 4 experimental tumors (RIF1, B16, EMT6/KU, SCCVII) of various sizes implanted subcutaneously (sc) or intradermally (id) were compared under identical conditions by using the paired survival curve assay method. The two survival curves for tumors in air-breathing and asphyxiated mice were almost parallel for EMT6/KU and SCCVII tumors, but not for RIF1 and B16 tumors. Therefore, hypoxic fractions were estimated by fitting the best parallel lines to the two sets of survival data. The values for 10 mm-diameter sc tumors in the hind legs of syngeneic mice were 4.7% for RIF1, 4.5% for B16, 14% for EMT6/KU, and 8.5% for SCCVII. The variation of the values is quite small in spite of the variety of biological characteristics of these tumors. Histological examination revealed that EMT6/KU and B16 tumors contained large necrotic areas, while SCCVII and RIF1 had small areas of necrosis. Thus, the hypoxic fraction and the proportion of necrosis in the histological specimens were not clearly correlated. The values for 6 mm and 16 mm sc EMT6/KU tumors were 5.9 and 22%, respectively, while that for 6 mm id tumors was 16%. The values for 5 mm and 18 mm sc SCCVII tumors were 0.86 and 8.4%, respectively. These results indicated that: (1) id EMT6/KU tumors had a higher hypoxic fraction than sc ones of the same size; (2) the hypoxic fraction increased with increase in tumor size in EMT6/KU tumors, while it reached a plateau at a certain size in SCVII tumors.

Entities:  

Mesh:

Year:  1986        PMID: 3095287

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  21 in total

1.  Adenosine-5'-triphosphate levels in experimental CaNT and Fib/t tumours of varying volume and degree of hypoxia.

Authors:  D Szeinfeld
Journal:  Experientia       Date:  1988-03-15

2.  Fractionated stereotactic radiotherapy for metastatic brain tumors that recurred after gamma knife radiosurgery results in acceptable toxicity and favorable local control.

Authors:  Akifumi Miyakawa; Yuta Shibamoto; Shinya Takemoto; Toru Serizawa; Shinya Otsuka; Tatsuo Hirai
Journal:  Int J Clin Oncol       Date:  2016-11-08       Impact factor: 3.402

3.  An attempt to enhance chemosensitivity of quiescent cell populations in solid tumors by combined treatment with nicotinamide and carbogen.

Authors:  S Masunaga; K Ono; M Akaboshi; K Kawai; K Akuta; M Takagaki; M Suzuki; Y Kinashi; M Abe
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo.

Authors:  R Murata; Y Shibamoto; S Miyauchi; M Hirohashi; T Takagi; K Sasai; N Oya; M Hiraoka
Journal:  Br J Cancer Suppl       Date:  1996-07

5.  Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience.

Authors:  Yukiko Hattori; Taro Murai; Hiromitsu Iwata; Kaoru Uchiyama; Mikio Mimura; Eriko Kato; Rumi Murata; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2016-02-06       Impact factor: 2.374

6.  Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.

Authors:  Shin-ichiro Masunaga; Hideko Nagasawa; Kenji Nagata; Minoru Suzuki; Yoshihiro Uto; Hitoshi Hori; Yuko Kinashi; Koji Ono
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-22       Impact factor: 4.553

7.  KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

Authors:  K Sasai; Y Shibamoto; M Takahashi; L Zhou; H Hori; H Nagasawa; T Shibata; S Inayama; M Abe
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Radiotherapy for metastatic brain tumors.

Authors:  Yuta Shibamoto; Chikao Sugie; Hiromitsu Iwata
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

9.  Detection of DNA-protein crosslinks (DPCs) by novel direct fluorescence labeling methods: distinct stabilities of aldehyde and radiation-induced DPCs.

Authors:  Mahmoud I Shoulkamy; Toshiaki Nakano; Makiko Ohshima; Ryoichi Hirayama; Akiko Uzawa; Yoshiya Furusawa; Hiroshi Ide
Journal:  Nucleic Acids Res       Date:  2012-06-22       Impact factor: 16.971

10.  Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size.

Authors:  Fumiya Baba; Yuta Shibamoto; Hiroyuki Ogino; Rumi Murata; Chikao Sugie; Hiromitsu Iwata; Shinya Otsuka; Katsura Kosaki; Aiko Nagai; Taro Murai; Akifumi Miyakawa
Journal:  Radiat Oncol       Date:  2010-09-17       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.